The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss ... the FDA approval of Novo ...

Compounding pharmacies have been allowed to make generic semaglutide ... how much the FDA will enforce this new regulation.” What to do if you rely on compounded weight-loss drugs There ...

Study: Increased vision impairment reports linked to semaglutide: analysis of FDA adverse ... as data for the obesity-specific formulation Wegovy were limited. Rapid weight loss (>10% body weight ...

NORTH CAROLINA -- A warning to consumers about fake Ozempic (semaglutide ... Besides the FDA, the FBI also issued this warning about fake compounding weight loss drugs on the market.